Description: Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark.
Home Page: www.bavarian-nordic.com
Philip Heymans Alle 3
Hellerup,
2900
Denmark
Phone:
45 33 26 83 83
Officers
| Name | Title |
|---|---|
| Dr. Paul John Chaplin MSc, Ph.D. | CEO & Pres |
| Mr. Henrik Juuel M.Sc. | CFO & Exec. VP |
| Mr. Russell Thirsk | Exec. VP & COO |
| Mr. Rolf Sass Sørensen | VP of Investor Relations & Communications |
| Ms. Anu Helena Kerns | Exec. VP & Chief People Officer |
| Mr. Jean-Christophe May | Exec. VP & Chief Commercial Officer |
| Dr. Laurence De Moerlooze | Exec. VP & Chief Medical Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 4.99 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.198 |
| Price-to-Sales TTM: | 0.9318 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 917 |